title: Ð Ð°Ð·ÑÐ°Ð±Ð¾ÑÐºÐ° Ð¿Ð¾Ð´Ñ Ð¾Ð´Ð¾Ð² Ðº Ð´Ð¾Ð·Ð¸Ð¼ÐµÑÑÐ¸Ð¸ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð², Ð¿ÑÐ¾Ñ Ð¾Ð´ÑÑÐ¸Ñ ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð½ÑÑ Ð´Ð¸Ð°Ð³Ð½Ð¾ÑÑÐ¸ÐºÑ Ñ 89Zr-Ramucirumab (89Zr-Ð Ð°Ð¼ÑÑÐ¸ÑÑÐ¼Ð°Ð±)
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð±Ð°ÐºÐ°Ð»Ð°Ð²ÑÐ°
titleType: Subtitle
title: Development of approaches to dosimetry of patients undergoing radionuclide diagnostics with 89Zr-Ramucirumab (89Zr-Ramucirumab)
Creators: name: ÐÐ°ÑÑÐ·Ð±Ð°ÐµÐ²Ð°, ÐÐ°ÑÑÐ°
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2021
Subjects: ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð½Ð°Ñ Ð´Ð¸Ð°Ð³Ð½Ð¾ÑÑÐ¸ÐºÐ°
Ð¼Ð¾Ð½Ð¾ÐºÐ»Ð¾Ð½Ð°Ð»ÑÐ½ÑÐµ Ð°Ð½ÑÐ¸ÑÐµÐ»Ð°
ÑÐ¸ÑÐºÐ¾Ð½Ð¸Ð¹
Ð±Ð¸Ð¾ÑÐ°ÑÐ¿ÑÐµÐ´ÐµÐ»ÐµÐ½Ð¸Ðµ ÑÐ°Ð´Ð¸Ð¾ÑÐ°ÑÐ¼Ð¿ÑÐµÐ¿Ð°ÑÐ°ÑÐ¾Ð²
ÐºÐ°Ð¼ÐµÑÐ½ÑÐµ Ð¼Ð¾Ð´ÐµÐ»Ð¸
Ð¿Ð¾Ð³Ð»Ð¾ÑÐµÐ½Ð½ÑÐµ Ð´Ð¾Ð·Ñ
radionuclide diagnostics
monoclonal antibodies
zirconium
biodistribution of radio-pharmaceuticals
chamber models
absorbed doses

description: ÐÐ°Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¿Ð¾ÑÐ²ÑÑÐµÐ½Ð° Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸Ñ ÑÐ°ÑÐ¼Ð°ÐºÐ¾ÐºÐ¸Ð½ÐµÑÐ¸ÐºÐ¸ Ð¸ ÑÐ°ÑÐ¼Ð°ÐºÐ¾Ð´Ð¸Ð½Ð°Ð¼Ð¸ÐºÐ¸ 89Zr-Ð Ð°Ð¼ÑÑÐ¸ÑÑÐ¼Ð°Ð± Ñ Ð´Ð°Ð»ÑÐ½ÐµÐ¹ÑÐµÐ¹ ÑÐ°Ð·ÑÐ°Ð±Ð¾ÑÐºÐ¾Ð¹ Ð¼ÐµÑÐ¾Ð´Ð¾Ð² Ð¾ÑÐµÐ½ÐºÐ¸ Ð¿Ð¾Ð³Ð»Ð¾ÑÐµÐ½Ð½ÑÑ Ð´Ð¾Ð·. ÐÐ°Ð´Ð°ÑÐ¸, ÐºÐ¾ÑÐ¾ÑÑÐµ ÑÐµÑÐ°Ð»Ð¸ÑÑ Ð² ÑÐ¾Ð´Ðµ Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸Ñ: 1. ÐÐ·ÑÑÐµÐ½Ð¸Ðµ Ð»Ð¸ÑÐµÑÐ°ÑÑÑÑ Ð¿Ð¾ Ð±Ð¸Ð¾ÑÐ°ÑÐ¿ÑÐµÐ´ÐµÐ»ÐµÐ½Ð¸Ñ 89Zr-ÑÐ°Ð¼ÑÑÐ¸ÑÑÐ¼Ð°Ð± Ð¸ ÑÐ¸ÑÑÐ¾Ð³Ð¾ 89Zr Ð¸ Ð¼ÐµÑÐ¾Ð´Ð¸ÐºÐ°Ð¼ Ð¾ÑÐµÐ½ÐºÐµ Ð¿Ð¾Ð³Ð»Ð¾ÑÐµÐ½Ð½ÑÑ Ð´Ð¾Ð· Ð´Ð»Ñ ÑÐ°Ð´Ð¸Ð¾ÑÐ°ÑÐ¼Ð¿ÑÐµÐ¿Ð°ÑÐ°ÑÐ¾Ð² Ð½Ð° Ð¾ÑÐ½Ð¾Ð²Ðµ Ð¼Ð¾Ð½Ð¾ÐºÐ»Ð¾Ð½Ð°Ð»ÑÐ½ÑÑ Ð°Ð½ÑÐ¸ÑÐµÐ», Ð¼ÐµÑÐµÐ½Ð½ÑÑ ÑÐ¸ÑÐºÐ¾Ð½Ð¸ÐµÐ¼-89. 2. ÐÐ¾ÑÑÑÐ¾ÐµÐ½Ð¸Ðµ ÐºÑÐ¸Ð²ÑÑ Ð²ÑÐ²ÐµÐ´ÐµÐ½Ð¸Ñ-Ð½Ð°ÐºÐ¾Ð¿Ð»ÐµÐ½Ð¸Ñ Ð Ð¤Ð Ð´Ð»Ñ ÑÐ°Ð·Ð½ÑÑ Ð¾ÑÐ³Ð°Ð½Ð¾Ð² Ð½Ð° Ð¾ÑÐ½Ð¾Ð²Ð°Ð½Ð¸Ðµ Ð´Ð°Ð½Ð½ÑÑ Ð¸Ð· Ð»Ð¸ÑÐµÑÐ°ÑÑÑÐ½Ð¾Ð³Ð¾ Ð¾Ð±Ð·Ð¾ÑÐ°. 3. Ð Ð°ÑÑÑÑ ÑÐµÐ¿Ð¾ÑÐºÐ¸ ÑÐ°ÑÐ¿Ð°Ð´Ð° 89Zr. 4. Ð Ð°ÑÑÑÑ Ð¸Ð½ÑÐµÐ³ÑÐ°Ð»ÑÐ½Ð¾Ð¹ Ð°ÐºÑÐ¸Ð²Ð½Ð¾ÑÑÐ¸ Ð¸ Ð¾Ð¿ÑÐµÐ´ÐµÐ»ÐµÐ½Ð¸Ðµ Ð¿Ð¾Ð³Ð»Ð¾ÑÐµÐ½Ð½ÑÑ Ð´Ð¾Ð·. 5. ÐÐ½Ð°Ð»Ð¸Ð· ÑÑÐ°Ð½Ð´Ð°ÑÑÐ½Ð¾Ð³Ð¾ Ð¾ÑÐºÐ»Ð¾Ð½ÐµÐ½Ð¸Ñ Ð¿Ð¾Ð»ÑÑÐµÐ½Ð½ÑÑ Ð´Ð¾Ð· Ð¾Ñ Ð´Ð¾Ð· Ð¸Ð· Ð´ÑÑÐ³Ð¸Ñ Ð¸ÑÑÐ¾ÑÐ½Ð¸ÐºÐ¾Ð². Ð Ð°Ð±Ð¾ÑÐ° Ð¿ÑÐ¾Ð²ÐµÐ´ÐµÐ½Ð° Ð½Ð° Ð±Ð°Ð·Ðµ Ð»Ð°Ð±Ð¾ÑÐ°ÑÐ¾ÑÐ¸Ð¸ ÑÐ°Ð´Ð¸Ð°ÑÐ¸Ð¾Ð½Ð½Ð¾Ð¹ Ð³Ð¸Ð³Ð¸ÐµÐ½Ñ Ð¼ÐµÐ´Ð¸ÑÐ¸Ð½ÑÐºÐ¸Ñ Ð¾ÑÐ³Ð°Ð½Ð¸Ð·Ð°ÑÐ¸Ð¹ Ð¤ÐÐ£Ð ÐÐÐÐ Ð Ð¸Ð¼. Ð.Ð. Ð Ð°Ð¼Ð·Ð°ÐµÐ²Ð°. ÐÑÐ»Ð¸ Ð¿ÑÐ¾Ð²ÐµÐ´ÐµÐ½Ñ ÑÐ°ÑÑÑÑÑ, Ð¿Ð¾ÐºÐ°Ð·ÑÐ²Ð°ÑÑÐ¸Ðµ Ð² ÐºÐ°ÐºÐ¸Ñ Ð¾ÑÐ³Ð°Ð½Ð°Ñ Ð½Ð°Ð±Ð»ÑÐ´Ð°Ð»Ð¾ÑÑ Ð±Ð¾Ð»ÑÑÐµÐµ ÑÐ¾Ð´ÐµÑÐ¶Ð°Ð½Ð¸Ðµ ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð°, Ð²ÐºÐ»Ð°Ð´ Ð´Ð¾ÑÐµÑÐ½Ð¸Ñ ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð¾Ð² Ð² Ð¿Ð¾Ð³Ð»Ð¾ÑÐµÐ½Ð½ÑÑ Ð´Ð¾Ð·Ñ Ð¸ ÑÐ°Ð¼Ñ Ð¿Ð¾Ð³Ð»Ð¾ÑÐµÐ½Ð½ÑÑ Ð´Ð¾Ð·Ñ Ð² Ð¾ÑÐ³Ð°Ð½Ð°Ñ. ÐÑÐ¸ ÑÐ°ÑÑÑÑÐ°Ñ Ð¸ÑÐ¿Ð¾Ð»ÑÐ·Ð¾Ð²Ð°Ð»Ð¸ÑÑ Ð²Ð¾Ð·Ð¼Ð¾Ð¶Ð½Ð¾ÑÑÐ¸ MS Excel Ð¸ IDAC-Dose 2.1, Ð° Ð³ÑÐ°ÑÐ¸ÐºÐ¸ ÑÑÑÐ¾Ð¸Ð»Ð¸ÑÑ Ð¸ Ð¾Ð±ÑÐ°Ð±Ð°ÑÑÐ²Ð°Ð»Ð¸ÑÑ Ð¿ÑÐ¸ Ð¿Ð¾Ð¼Ð¾ÑÐ¸ Origin Lab. ÐÐ½Ð°Ð»Ð¸Ð· Ð¿ÑÐ¾Ð¸Ð·Ð²Ð¾Ð´Ð¸Ð»ÑÑ Ð½Ð° Ð¾ÑÐ½Ð¾Ð²Ðµ ÑÑÐ°Ð½Ð´Ð°ÑÑÐ½Ð¾Ð³Ð¾ Ð¾ÑÐºÐ»Ð¾Ð½ÐµÐ½Ð¸Ñ. Ð ÑÐµÐ·ÑÐ»ÑÑÐ°ÑÐµ Ð±ÑÐ»Ð¸ Ð¿ÑÐ¾Ð°Ð½Ð°Ð»Ð¸Ð·Ð¸ÑÐ¾Ð²Ð°Ð½Ñ Ð´Ð°Ð½Ð½ÑÐµ Ð¾ Ð±Ð¸Ð¾ÑÐ°ÑÐ¿ÑÐµÐ´ÐµÐ»ÐµÐ½Ð¸Ðµ 89Zr-ÑÐ°Ð¼ÑÑÐ¸ÑÑÐ¼Ð°Ð±, Ð¾ÑÐµÐ½ÐµÐ½Ñ Ð¿Ð¾Ð³Ð»Ð¾ÑÐµÐ½Ð½ÑÐµ Ð´Ð¾Ð·Ñ Ð² Ð¾ÑÐ³Ð°Ð½Ð°Ñ Ð¸ ÑÐ´ÐµÐ»Ð°Ð½Ñ Ð²ÑÐ²Ð¾Ð´Ñ Ð¾ Ð¿ÑÐ¸Ð¼ÐµÐ½Ð¸Ð¼Ð¾ÑÑÑ ÑÐ°Ð·ÑÐ°Ð±Ð¾ÑÐ°Ð½Ð½Ð¾Ð³Ð¾ Ð½Ð°Ð¼Ð¸ Ð¿Ð¾Ð´ÑÐ¾Ð´Ð° Ðº Ð´Ð¾Ð·Ð¸Ð¼ÐµÑÑÐ¸Ð¸ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð², Ð¿ÑÐ¾ÑÐ¾Ð´ÑÑÐ¸Ñ Ð´Ð¸Ð°Ð³Ð½Ð¾ÑÑÐ¸ÐºÑ 89Zr-ÑÐ°Ð¼ÑÑÐ¸ÑÑÐ¼Ð°Ð±. ÐÐ° Ð¾ÑÐ½Ð¾Ð²Ð°Ð½Ð¸Ðµ Ð¿ÑÐ¾Ð²ÐµÐ´ÐµÐ½Ð½ÑÑ Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸Ð¹ Ð±ÑÐ»Ð¾ Ð¿ÑÐ¸Ð½ÑÑÐ¾ ÑÐµÑÐµÐ½Ð¸Ðµ Ð¾ Ð¿ÑÐ¾Ð²ÐµÐ´ÐµÐ½Ð¸Ðµ Ð´Ð¾Ð¿Ð¾Ð»Ð½Ð¸ÑÐµÐ»ÑÐ½ÑÑ Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸Ð¹ Ð¿Ð¾ Ð¾ÑÐµÐ½ÐºÐµ Ð±Ð¸Ð¾ÑÐ°ÑÐ¿ÑÐµÐ´ÐµÐ»ÐµÐ½Ð¸Ñ Ð´Ð°Ð½Ð½Ð¾Ð³Ð¾ ÑÐ°Ð´Ð¸Ð¾ÑÐ°ÑÐ¼Ð¿ÑÐµÐ¿Ð°ÑÐ°ÑÐ° Ð² Ð¾ÑÐ³Ð°Ð½Ð¸Ð·Ð¼Ðµ, ÑÐ°Ðº ÐºÐ°Ðº Ð½Ð° Ð´Ð°Ð½Ð½ÑÐ¹ Ð¼Ð¾Ð¼ÐµÐ½Ñ Ð½ÐµÐ´Ð¾ÑÑÐ°ÑÐ¾ÑÐ½Ð¾ Ð´Ð°Ð½Ð½ÑÑ Ð´Ð»Ñ Ð¿ÑÐ¾Ð²ÐµÐ´ÐµÐ½Ð¸Ñ ÐºÐ°ÑÐµÑÑÐ²ÐµÐ½Ð½Ð¾Ð¹ Ð¾ÑÐµÐ½ÐºÐ¸ Ð¿Ð¾Ð³Ð»Ð¾ÑÐµÐ½Ð½Ð¾Ð¹ Ð´Ð¾Ð·Ñ Ð±ÐµÐ· Ð¼Ð½Ð¾Ð¶ÐµÑÑÐ²Ð° Ð´Ð¾Ð¿ÑÑÐµÐ½Ð¸Ð¹.
description: This work is devoted to the study of the pharmacokinetics and pharmacodynamics of 89Zr-Ramucirumab with the further development of methods for assessing absorbed doses. The tasks that were solved during the study: 1. Study of the literature on biodistribution of 89Zr-Ramucirumab and pure 89Zr and methods for assessing absorbed doses for radiopharmaceuticals based on monoclonal antibodies labeled with zirconium-89. 2. Plotting the radiopharmaceutical excretion-accumulation curves for different organs on the basis of data from the literature review. 3. Calculation of the decay chain of 89Zr. 4. Calculation of integral activity and determination of doses. 5. Analysis of the standard deviation of received doses from doses from other sources. The work was carried out on the basis of the laboratory of radiation hygiene of medical organizations Research Institute of Radiation Hygiene. Calculations were carried out showing in which organs the greater content of the radionuclide was observed, the contribution of daughter radionuclides to the absorbed dose and the absorbed dose itself. In the calculations, the capabilities of MS Excel and IDAC-Dose 2.1 were used, and the graphs were built and processed using Origin Lab. The analysis was performed based on the standard deviation. As a result, we analyzed the data on the biodistribution of 89Zr-Ramucirumab, estimated the absorbed doses in organs, and made conclusions about the applicability of our approach to dosimetry of patients undergoing 89Zr-Ramucirumab diagnostics. On the basis of the conducted studies, it was decided to conduct additional studies to assess the biodistribution of this radiopharmaceutical in the body, since at the moment there is not enough data to conduct a qualitative assessment of the absorbed dose without many assumptions.